Testicular germ cell tumours: The paradigm of chemo-sensitive solid tumours

International Journal of Biochemistry and Cell Biology

Volumn 37, Issue 12, 2005, Pages 2437-2456

  Di Pietro, Alessandra ^a,b   De Vries, Elisabeth G E ^a   Gietema, Jourik A ^a   Spierings, Diana C J ^a   De Jong, Steven ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Apoptosis; Cell cycle; Chemotherapy; Germ cell tumours; p21; p53

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CISPLATIN; CYTOTOXIC AGENT; DEATH RECEPTOR; DOXORUBICIN; IMATINIB; MELPHALAN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; TAXANE DERIVATIVE;

APOPTOSIS; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHEMOSENSITIVITY; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; GENETICS; GERM CELL; GERM CELL TUMOR; HUMAN; MALE; METASTASIS; MITOCHONDRION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; TESTIS CANCER; TRANSACTIVATION; WILD TYPE;

EID: 25844453939     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2005.06.014     Document Type: Short Survey

References (236)

1. M.L. Agarwal, A. Agarwal, W.R. Taylor, and G.R. Stark p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts Proc. Natl. Acad. Sci. U.S.A. 92 1995 8493 8497
2. A.M. Al Ghamdi, and M.A. Jewett Stage I nonseminomatous germ cell tumors: The case for management by risk stratification Can. J. Urol. 12 Suppl. 1 2005 62 65
3. D. Alarcon-Vargas, and Z. Ronai p53-Mdm2 - The affair that never ends Carcinogenesis 23 2002 541 547
4. H. Amsalem, M. Nadjari, D. Prus, N. Hiller, and A. Benshushan Growing teratoma syndrome vs chemotherapeutic retroconversion: Case report and review of the literature Gynecol. Oncol. 92 2004 357 360
5. P.W. Andrews, I. Damjanov, D. Simon, G.S. Banting, C. Carlin, and N.C. Dracopoli Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2 Differentiation in vivo and in vitro Lab. Invest. 50 1984 147 162
6. P.W. Andrews, P.N. Goodfellow, L.H. Shevinsky, D.L. Bronson, and B.B. Knowles Cell-surface antigens of a clonal human embryonal carcinoma cell line: Morphological and antigenic differentiation in culture Int. J. Cancer 29 1982 523 531
7. M. Asada, T. Yamada, H. Ichijo, D. Delia, K. Miyazono, and K. Fukumuro Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation EMBO J. 18 1999 1223 1234
8. T.K. Bagui, S. Mohapatra, E. Haura, and W.J. Pledger P27Kip1 and p21Cip1 are not required for the formation of active D cyclin-cdk4 complexes Mol. Cell Biol. 23 2003 7285 7290
9. J. Bartkova, C. Lukas, C.S. Sorensen, E.R. Meyts, N.E. Skakkebaek, and J. Lukas Deregulation of the RB pathway in human testicular germ cell tumours J. Pathol. 200 2003 149 156
10. J. Bartkova, E. Rajpert-De Meyts, N.E. Skakkebaek, and J. Bartek D-type cyclins in adult human testis and testicular cancer: Relation to cell type, proliferation, differentiation, and malignancy J. Pathol. 187 1999 573 581
11. J. Bartkova, M. Thullberg, E. Rajpert-De Meyts, N.E. Skakkebaek, and J. Bartek Cell cycle regulators in testicular cancer: Loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours Int. J. Cancer 85 2000 370 375
12. D. Bellgrau, D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke A role for CD95 ligand in preventing graft rejection Nature 377 1995 630 632
13. M. Bennett, K. Macdonald, S.W. Chan, J.P. Luzio, R. Simari, and P. Weissberg Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis Science 282 1998 290 293
14. D. Bergamaschi, M. Gasco, L. Hiller, A. Sullivan, N. Syed, and G. Trigiante p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis Cancer Cell 3 2003 387 402
15. C. Bernstein, H. Bernstein, C.M. Payne, and H. Garewal DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis Mutat. Res. 511 2002 145 178
16. T.L. Beumer, H.L. Roepers-Gajadien, L.S. Gademan, D.H. Rutgers, and D.G. de Rooij P21(Cip1/WAF1) expression in the mouse testis before and after X irradiation Mol. Reprod. Dev. 47 1997 240 247
17. E. Beurel, M. Kornprobst, M.J. Blivet-Van Eggelpoel, C. Ruiz-Ruiz, A. Cadoret, and J. Capeau GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression Exp. Cell Res. 300 2004 354 364
18. S. Bosari, G. Viale, M. Roncalli, D. Graziani, G. Borsani, and A.K. Lee p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma Am. J. Pathol. 147 1995 790 798
19. G.J. Bosl, E. Dmitrovsky, V.E. Reuter, F. Samaniego, E. Rodriguez, and N.L. Geller Isochromosome of the short arm of chromosome 12: Clinically useful markers for male germ cell tumors J. Natl. Cancer Inst. 81 1989 1874 1878
20. B. Bothner, W.S. Lewis, E.L. DiGiammarino, J.D. Weber, S.J. Bothner, and RW. Kriwacki Defining the molecular basis of Arf and Hdm2 interactions J. Mol. Biol. 314 2001 263 277
21. D.L. Bronson, P.W. Andrews, D. Solter, J. Cervenka, P.H. Lange, and E.E. Fraley Cell line derived from a metastasis of a human testicular germ cell tumor Cancer Res. 40 1980 2500 2506
22. H. Burger, K. Nooter, A.W. Boersma, C.J. Kortland, and G. Stoter Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines Int. J. Cancer 73 1997 592 599
23. H. Burger, K. Nooter, A.W. Boersma, K.E. van Wingerden, L.H. Looijenga, and A.G. Jochemsen Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines Int. J. Cancer 81 1999 620 628
24. H. Burger, K. Nooter, A.W. Boersma, K.E. van Wingerden, L.H. Looijenga, and A.G. Jochemsen Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines Int. J. Cancer 81 1999 620 628
25. R.S. Chaganti, and J. Houldsworth Genetics and biology of adult human male germ cell tumors Cancer Res. 60 2000 1475 1482
26. P. Chaubert, L. Guillou, A.M. Kurt, M.M. Bertholet, G. Metthez, and H.J. Leisinger Frequent p16INK4 (MTS1) gene inactivation in testicular germ cell tumors Am. J. Pathol. 151 1997 859 865
27. S.P. Chellappan, S. Hiebert, M. Mudryj, J.M. Horowitz, and J.R. Nevins The E2F transcription factor is a cellular target for the RB protein Cell 65 1991 1053 1061
28. H. Chemes, P.M. Muzulin, M.C. Venara, M.C. Mulhmann, M. Martinez, and M. Gamboni Early manifestations of testicular dysgenesis in children: Pathological phenotypes, karyotype correlations and precursor stages of tumour development APMIS 111 2003 12 23
29. C.M. Chresta, J.R. Masters, and J.A. Hickman Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio Cancer Res. 56 1996 1834 1841
30. J. Classen, R. Souchon, T. Hehr, and M. Bamberg Treatment of early stage testicular seminoma J. Cancer Res. Clin. Oncol. 127 2001 475 481
31. O. Coqueret New roles for p21 and p27 cell-cycle inhibitors: A function for each cell compartment? Trends Cell Biol. 13 2003 65 70
32. C.L. Corless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J. Clin. Oncol. 22 2004 3813 3825
33. A. Costanzo, P. Merlo, N. Pediconi, M. Fulco, V. Sartorelli, and P.A. Cole DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes Mol. Cell. 9 2002 175 186
34. G. D'Orazi, B. Cecchinelli, T. Bruno, I. Manni, Y. Higashimoto, and S. Saito Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis Nat. Cell. Biol. 4 2002 11 19
35. I. Damjanov, B. Horvat, and Z. Gibas Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT Lab Invest. 68 1993 220 232
36. M.W. Datta, E. Macri, S. Signoretti, A.A. Renshaw, and M. Loda Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression Mod. Pathol. 14 2001 437 442
37. R.P. Dellavalle, T.B. Egbert, A. Marchbank, L.J. Su, L.A. Lee, and P. Walsh CUSP/p63 expression in rat and human tissues J. Dermatol. Sci. 27 2001 82 87
38. B.E. Deverman, B.L. Cook, S.R. Manson, R.A. Niederhoff, E.M. Langer, and I. Rosova Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage Cell 111 2002 51 62
39. M. Devouassoux-Shisheboran, C. Mauduit, R. Bouvier, F. Berger, M. Bouras, and J.P. Droz Expression of hMLH1 and hMSH2 and assessment of microsatellite instability in testicular and mediastinal germ cell tumours Mol. Hum. Reprod. 7 2001 1099 1105
40. K.P. Dieckmann, and NE. Skakkebaek Carcinoma in situ of the testis: Review of biological and clinical features Int. J. Cancer 83 1999 815 822
41. D. Duro, O. Bernard, V.V. Della, R. Berger, and C.J. Larsen A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies Oncogene 11 1995 21 29
42. N. Dyson The regulation of E2F by pRB-family proteins Genes Dev. 12 1998 2245 2262
43. H. Eid, E. Institoris, L. Geczi, I. Bodrogi, and M. Bak mdm-2 expression in human testicular germ-cell tumors and its clinical value Anticancer Res. 19 1999 3485 3490
44. G.H. Enders The INK4a/ARF locus and human cancer Methods Mol. Biol. 222 2003 197 209
45. A.R. Evans, M. Limp-Foster, and M.R. Kelley Going APE over ref-1 Mutat. Res. 461 2000 83 108
46. M. Ferrer, T. Izeboud, C.G. Ferreira, S.W. Span, G. Giaccone, and F.A. Kruyt Cisplatin triggers apoptotic or nonapoptotic cell death in Fanconi anemia lymphoblasts in a concentration-dependent manner Exp. Cell Res. 286 2003 381 395
47. S.J. Field, F.Y. Tsai, F. Kuo, A.M. Zubiaga, W.G. Kaelin Jr., and D.M. Livingston E2F-1 functions in mice to promote apoptosis and suppress proliferation Cell 85 1996 549 561
48. M. Fleischhacker, T. Strohmeyer, Y. Imai, D.J. Slamon, and H.P. Koeffler Mutations of the p53 gene are not detectable in human testicular tumors Mod. Pathol. 7 1994 435 439
49. J. Fogh Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors Natl. Cancer Inst. Monogr. 1978 5 9
50. T. Fojo p53 as a therapeutic target: Unresolved issues on the road to cancer therapy targeting mutant p53 Drug Resist. Updat. 5 2002 209 216
51. S. Francavilla, P. D'Abrizio, G. Cordeschi, F. Pelliccione, S. Necozione, and S. Ulisse Fas expression correlates with human germ cell degeneration in meiotic and post-meiotic arrest of spermatogenesis Mol. Hum. Reprod. 8 2002 213 220
52. D.S. Franklin, V.L. Godfrey, H. Lee, G.I. Kovalev, R. Schoonhoven, and S. Chen-Kiang CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis Genes Dev. 12 1998 2899 2911
53. C. Friesen, S. Fulda, and K.M. Debatin Cytotoxic drugs and the CD95 pathway Leukemia 13 1999 1854 1858
54. M.B. Gariboldi, R. Ravizza, L. Riganti, S. Meschini, A. Calcabrini, and M. Marra Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines Int. J. Oncol. 22 2003 1057 1064
55. M. Gasco, and T. Crook p53 family members and chemoresistance in cancer: What we know and what we need to know Drug Resist. Updat. 6 2003 323 328
56. S. Gaubatz, G.J. Lindeman, S. Ishida, L. Jakoi, J.R. Nevins, and D.M. Livingston E2F4 and E2F5 play an essential role in pocket protein-mediated G1 control Mol. Cell 6 2000 729 735
57. J.I. Geller, K. Szekely-Szucs, I. Petak, B. Doyle, and J.A. Houghton P21Cip1 is a critical mediator of the cytotoxic action of thymidylate synthase inhibitors in colorectal carcinoma cells Cancer Res. 64 2004 6296 6303
58. A.J. Giaccia, and M.B. Kastan The complexity of p53 modulation: Emerging patterns from divergent signals Genes Dev. 12 1998 2973 2983
59. J.G. Gong, A. Costanzo, H.Q. Yang, G. Melino, W.G. Kaelin Jr., and M. Levrero The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage Nature 399 1999 806 809
60. S. Gori, S. Porrozzi, F. Roila, G. Gatta, U. De Giorgi, and M. Marangolo Germ cell tumours of the testis Crit. Rev. Oncol. Hematol. 53 2005 141 164
61. M. Gosland, B. Lum, J. Schimmelpfennig, J. Baker, and M. Doukas Insights into mechanisms of cisplatin resistance and potential for its clinical reversal Pharmacotherapy 16 1996 16 39
62. V. Gottifredi, and C. Prives Molecular biology Getting p53 out of the nucleus Science 292 2001 1851 1852
63. L. Guillou, A. Estreicher, P. Chaubert, J. Hurlimann, A.M. Kurt, and G. Metthez Germ cell tumors of the testis overexpress wild-type p53 Am. J. Pathol. 149 1996 1221 1228
64. G. Hamer, I.S. Gademan, H.B. Kal, and D.G. de Rooij Role for c-Abl and p73 in the radiation response of male germ cells Oncogene 20 2001 4298 4304
65. S. Hara, H. Miyake, I. Nakamura, S. Arakawa, S. Kamidono, and I. Hara Increased Fas ligand expression in the tumor tissue and serum of patients with testicular germ cell tumors with seminomatous elements Urology 58 2001 471 476
66. J.W. Harper, S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.H. Tsai, and P. Zhang Inhibition of cyclin-dependent kinases by p21 Mol. Biol. Cell 6 1995 387 400
67. Y. Hatta, T. Hirama, S. Takeuchi, E. Lee, E. Pham, and C.W. Miller Alterations of the p16 (MTS1) gene in testicular, ovarian, and endometrial malignancies J. Urol. 154 1995 1954 1957
68. K. Heimdal, H. Olsson, S. Tretli, S.D. Fossa, A.L. Borresen, and D.T. Bishop A segregation analysis of testicular cancer based on Norwegian and Swedish families Br. J. Cancer 75 1997 1084 1087
69. M.C. Heinrich, C.D. Blanke, B.J. Druker, and C.L. Corless Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies J. Clin. Oncol. 20 2002 1692 1703
70. K. Hemminki, and X. Li Familial risk in testicular cancer as a clue to a heritable and environmental aetiology Br. J. Cancer 90 2004 1765 1770
71. K. Hibi, B. Trink, M. Patturajan, W.H. Westra, O.L. Caballero, and D.E. Hill AIS is an oncogene amplified in squamous cell carcinoma Proc. Natl. Acad. Sci. U.S.A. 97 2000 5462 5467
72. A.P. Hikim, Y. Lue, C.M. Yamamoto, Y. Vera, S. Rodriguez, and P.H. Yen Key apoptotic pathways for heat-induced programmed germ cell death in the testis Endocrinology 144 2003 3167 3175
73. B.T. Hill, K.J. Scanlon, J. Hansson, A. Harstrick, M. Pera, and A.M. Fichtinger-Schepman Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients Eur. J. Cancer 30A 1994 832 837
74. T.G. Hofmann, A. Moller, H. Sirma, H. Zentgraf, Y. Taya, and W. Droge Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2 Nat. Cell Biol. 4 2002 1 10
75. B. Hogan, M. Fellous, P. Avner, and F. Jacob Isolation of a human teratoma cell line which expresses F9 antigen Nature 270 1977 515 518
76. M.F. Holzik, E.A. Rapley, H.J. Hoekstra, D.T. Sleijfer, I.M. Nolte, and R.H. Sijmons Genetic predisposition to testicular germ-cell tumours Lancet Oncol. 5 2004 363 371
77. R. Honda, and H. Yasuda Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 EMBO J. 18 1999 22 27
78. F. Honecker, F. Mayer, H. Stoop, J.W. Oosterhuis, S. Koch, and C. Bokemeyer Xeroderma pigmentosum group a protein and chemotherapy resistance in human germ cell tumors Lab. Invest. 83 2003 1489 1495
79. F. Honecker, J.W. Oosterhuis, F. Mayer, J.T. Hartmann, C. Bokemeyer, and L.H. Looijenga New insights into the pathology and molecular biology of human germ cell tumors World J. Urol. 22 2004 15 24
80. S. Honorio, A. Agathanggelou, N. Wernert, M. Rothe, E.R. Maher, and F. Latif Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours Oncogene 22 2003 461 466
81. R.A. Huddart, J. Titley, D. Robertson, G.T. Williams, A. Horwich, and C.S. Cooper Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines Eur. J. Cancer 31A 1995 739 746
82. S. Ikawa, A. Nakagawara, and Y. Ikawa p53 family genes: Structural comparison, expression and mutation Cell Death Differ. 6 1999 1154 1161
83. M. Irwin, M.C. Marin, A.C. Phillips, R.S. Seelan, D.I. Smith, and W. Liu Role for the p53 homologue p73 in E2F-1-induced apoptosis Nature 407 2000 645 648
84. M.S. Irwin, K. Kondo, M.C. Marin, L.S. Cheng, W.C. Hahn, and W.G. Kaelin Jr. Chemosensitivity linked to p73 function Cancer Cell 3 2003 403 410
85. M. Iwato, O. Tachibana, Y. Tohma, Y. Arakawa, H. Nitta, and M. Hasegawa Alterations of the INK4a/ARF locus in human intracranial germ cell tumors Cancer Res. 60 2000 2113 2115
86. M.W. Jackson, and S.J. Berberich MdmX protects p53 from Mdm2-mediated degradation Mol. Cell Biol. 20 2000 1001 1007
87. M.W. Jackson, M.S. Lindstrom, and S.J. Berberich MdmX binding to ARF affects Mdm2 protein stability and p53 transactivation J. Biol. Chem. 276 2001 25336 25341
88. F. Janus, N. Albrechtsen, I. Dornreiter, L. Wiesmuller, F. Grosse, and W. Deppert The dual role model for p53 in maintaining genomic integrity Cell Mol. Life Sci. 55 1999 12 27
89. D. Javelaud, and F. Besancon Inactivation of p21WAF1 sensitizes cells to apoptosis via an increase of both p14ARF and p53 levels and an alteration of the Bax/Bcl-2 ratio J. Biol. Chem. 277 2002 37949 37954
90. D. Javelaud, J. Wietzerbin, O. Delattre, and F. Besancon Induction of p21Waf1/Cip1 by TNFalpha requires NF-kappaB activity and antagonizes apoptosis in Ewing tumor cells Oncogene 19 2000 61 68
91. G.M. Jeffery, J.M. Theaker, A.H. Lee, R.M. Blaquiere, C.J. Smart, and G.M. Mead The growing teratoma syndrome Br. J. Urol. 67 1991 195 202
92. M.A. Jewett Biology of testicular tumors Urol. Clin. North Am. 4 1977 495 507
93. R.W. Johnstone, A.A. Ruefli, and S.W. Lowe Apoptosis: A link between cancer genetics and chemotherapy Cell 108 2002 153 164
94. R.H. Jones, and P.A. Vasey Part II: Testicular cancer - Management of advanced disease Lancet Oncol 4 2003 738 747
95. R.H. Jones, and P.A. Vasey Part II: Testicular cancer - Management of advanced disease Lancet Oncol. 4 2003 738 747
96. N. Jorgensen, E. Rajpert-De Meyts, N. Graem, J. Muller, A. Giwercman, and N.E. Skakkebaek Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells Lab. Invest. 72 1995 223 231
97. M. Kaghad, H. Bonnet, A. Yang, L. Creancier, J.C. Biscan, and A. Valent Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers Cell 90 1997 809 819
98. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc. Natl. Acad. Sci. U.S.A. 95 1998 8292 8297
99. K. Kemmer, C.L. Corless, J.A. Fletcher, L. McGreevey, A. Haley, and D. Griffith KIT mutations are common in testicular seminomas Am. J. Pathol. 164 2004 305 313
100. A.M. Kersemaekers, F. Mayer, M. Molier, P.C. van Weeren, J.W. Oosterhuis, and C. Bokemeyer Role of P53 and MDM2 in treatment response of human germ cell tumors J. Clin. Oncol. 20 2002 1551 1561
101. E.J. Kim, J.S. Park, and S.J. Um Identification and characterization of HIPK2 interacting with p73 and modulating functions of the p53 family in vivo J. Biol. Chem. 277 2002 32020 32028
102. B. Koberle, K.A. Grimaldi, A. Sunters, J.A. Hartley, L.R. Kelland, and J.R. Masters DNA repair capacity and cisplatin sensitivity of human testis tumour cells Int. J. Cancer 70 1997 551 555
103. B. Koberle, J. Payne, K.A. Grimaldi, J.A. Hartley, and J.R. Masters DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction Biochem. Pharmacol. 52 1996 1729 1734
104. T. Koji Male germ cell death in mouse testes: Possible involvement of Fas and Fas ligand Med. Electron Microsc. 34 2001 213 222
105. S. Koul, J.M. McKiernan, G. Narayan, J. Houldsworth, J. Bacik, and D.L. Dobrzynski Role of promoter hypermethylation in Cisplatin treatment response of male germ cell tumors Mol. Cancer 3 2004 16
106. S.M. Kraggerud, P. Aman, R. Holm, A.E. Stenwig, S.D. Fossa, and J.M. Nesland Alterations of the fragile histidine triad gene, FHIT, and its encoded products contribute to testicular germ cell tumorigenesis Cancer Res. 62 2002 512 517
107. U. Krug, A. Ganser, and H.P. Koeffler Tumor suppressor genes in normal and malignant hematopoiesis Oncogene 21 2002 3475 3495
108. Y. Kubo, K. Murao, K. Matsumoto, and S. Arase Molecular carcinogenesis of squamous cell carcinomas of the skin J. Med. Invest. 49 2002 111 117
109. R. Kukoski, B. Blonigen, E. Macri, A.A. Renshaw, M. Hoffman, and M. Loda p27 and cyclin E/D2 associations in testicular germ cell tumors: Implications for tumorigenesis Appl. Immunohistochem. Mol. Morphol. 11 2003 138 143
110. D.P. Lane p53 and human cancers Br. Med. Bull. 50 1994 582 599
111. J. Lee, J.H. Richburg, S.C. Younkin, and K. Boekelheide The Fas system is a key regulator of germ cell apoptosis in the testis Endocrinology 138 1997 2081 2088
112. S.H. Lee, M.S. Shin, W.S. Park, S.Y. Kim, S.M. Dong, and H.K. Lee Immunohistochemical analysis of Fas ligand expression in normal human tissues APMIS 107 1999 1013 1019
113. C. Liao, S.Q. Li, X. Wang, S. Muhlrad, A. Bjartell, and D.J. Wolgemuth Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors Int. J. Cancer 108 2004 654 664
114. K.M. Liefer, M.I. Koster, X.J. Wang, A. Yang, F. McKeon, and D.R. Roop Down-regulation of p63 is required for epidermal UV-B-induced apoptosis Cancer Res. 60 2000 4016 4020
115. G. Lilling, J. Nordenberg, V. Rotter, N. Goldfinger, S. Peller, and Y. Sidi Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells Cancer Invest. 20 2002 509 517
116. N.A. Lissy, P.K. Davis, M. Irwin, W.G. Kaelin, and S.F. Dowdy A common E2F-1 and p73 pathway mediates cell death induced by TCR activation Nature 407 2000 642 645
117. Y.X. Liu Control of spermatogenesis in primate and prospect of male contraception Arch. Androl. 51 2005 77 92
118. L.H. Looijenga, H. de Leeuw, M. van Oorschot, R.J. van Gurp, H. Stoop, and A.J. Gillis Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors Cancer Res. 63 2003 7674 7678
119. L.H. Looijenga, and J.W. Oosterhuis Pathogenesis of testicular germ cell tumours Rev. Reprod. 4 1999 90 100
120. R.A. Lothe, P. Peltomaki, N. Tommerup, S.D. Fossa, A.E. Stenwig, and A.L. Borresen Molecular genetic changes in human male germ cell tumors Lab. Invest. 73 1995 606 614
121. S.W. Lowe, H.E. Ruley, T. Jacks, and D.E. Housman p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell 74 1993 957 967
122. S.W. Lowe, and C.J. Sherr Tumor suppression by Ink4a-Arf: Progress and puzzles Curr. Opin. Genet. Dev. 13 2003 77 83
123. S.G. Lutzker, and A.J. Levine A functionally inactive p53 protein in teratocarcinoma cells is activated by either DNA damage or cellular differentiation Nat. Med. 2 1996 804 810
124. S.G. Lutzker, R. Mathew, and D.R. Taller A p53 dose-response relationship for sensitivity to DNA damage in isogenic teratocarcinoma cells Oncogene 20 2001 2982 2986
125. A. Madani, K. Kemmer, C. Sweeney, C. Corless, T. Ulbright, and M. Heinrich Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors Ann. Oncol. 14 2003 873 880
126. S. Mai, J. Hanley-Hyde, G.J. Rainey, T.I. Kuschak, J.T. Paul, and T.D. Littlewood Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression Neoplasia 1 1999 241 252
127. L. Mao, A. Merlo, G. Bedi, G.I. Shapiro, C.D. Edwards, and B.J. Rollins A novel p16INK4A transcript Cancer Res. 55 1995 2995 2997
128. J.R. Masters, and B. Koberle Curing metastatic cancer: Lessons from testicular germ-cell tumours Nat. Rev. Cancer 3 2003 517 525
129. J.R. Masters, R. Thomas, A.G. Hall, L. Hogarth, E.C. Matheson, and A.R. Cattan Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways Eur. J. Cancer 32A 1996 1248 1253
130. F. Mayer, A.J. Gillis, W. Dinjens, J.W. Oosterhuis, C. Bokemeyer, and L.H. Looijenga Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment Cancer Res. 62 2002 2758 2760
131. M. Meli, M. Tolomeo, N. D'Alessandro, S. Grimaudo, M. Notarbartolo, and G. Papoff Resistance to gemcitabine in a lymphoma cell line resistant to Fas-mediated apoptosis Anticancer Res. 24 2004 851 857
132. A.A. Mills, B. Zheng, X.J. Wang, H. Vogel, D.R. Roop, and A. Bradley p63 is a p53 homologue required for limb and epidermal morphogenesis Nature 398 1999 708 713
133. H. Miyake, I. Hara, K. Gohji, S. Arakawa, and S. Kamidono p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line Int. J. Oncol. 12 1998 469 473
134. M.B. Moller P27 in cell cycle control and cancer Leuk. Lymphoma 39 2000 19 27
135. M.C. Moroni, E.S. Hickman, E.L. Denchi, G. Caprara, E. Colli, and F. Cecconi Apaf-1 is a transcriptional target for E2F and p53 Nat. Cell Biol. 3 2001 552 558
136. T. Mueller, W. Voigt, H. Simon, A. Fruehauf, A. Bulankin, and A. Grothey Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer Cancer Res. 63 2003 513 521
137. M. Muller, S. Strand, H. Hug, E.M. Heinemann, H. Walczak, and W.J. Hofmann Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53 J. Clin. Invest. 99 1997 403 413
138. M. Muller, S. Wilder, D. Bannasch, D. Israeli, K. Lehlbach, and M. Li-Weber p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs J. Exp. Med. 188 1998 2033 2045
139. D. Munsch, R. Watanabe-Fukunaga, J.C. Bourdon, S. Nagata, E. May, and E. Yonish-Rouach Human and mouse Fas (APO-1/CD95) death receptor genes each contain a p53-responsive element that is activated by p53 mutants unable to induce apoptosis J. Biol. Chem. 275 2000 3867 3872
140. J.R. Nevins Toward an understanding of the functional complexity of the E2F and retinoblastoma families Cell Growth Differ. 9 1998 585 593
141. A. O'Brate, and P. Giannakakou The importance of p53 location: Nuclear or cytoplasmic zip code? Drug Resist Updat. 6 2003 313 322
142. R.A. Olie, B. Fenderson, K. Daley, J.W. Oosterhuis, J. Murphy, and L.H. Looijenga Glycolipids of human primary testicular germ cell tumours Br. J. Cancer 74 1996 133 140
143. R.A. Olie, L.H. Looijenga, L. Boerrigter, B. Top, S. Rodenhuis, and A. Langeveld N- and KRAS mutations in primary testicular germ cell tumors: Incidence and possible biological implications Genes Chromosomes Cancer 12 1995 110 116
144. G.O. Oosterhof, and J. Verlind Testicular tumours (nonseminomatous) BJU Int. 94 2004 1196 1201
145. J.W. Oosterhuis, S.M. Castedo, B. de Jong, C.J. Cornelisse, A. Dam, and D.T. Sleijfer Ploidy of primary germ cell tumors of the testis. Pathogenetic and clinical relevance Lab. Invest. 60 1989 14 21
146. Oosterhuis, J. W., Gillis A. J., & Looijenga L. H. (1997). In vitro survival, ras mutations, apoptosis and activation of the SAPK-pathway in human seminoma cells. John Libbey and Company Ltd.: London, I Appleyard. Ref Type: Serial (Book, Monograph), pp. 51-57.
147. C. Palumbo, K. van Roozendaal, A.J. Gillis, R.H. van Gurp, H. de Munnik, and J.W. Oosterhuis Expression of the PDGF alpha-receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues Implications for the early diagnosis of testicular germ cell tumours and for our understanding of regulatory mechanisms J. Pathol. 196 2002 467 477
148. M. Peckham Testicular cancer Acta Oncol. 27 1988 439 453
149. V. Pentikainen, K. Erkkila, and L. Dunkel Fas regulates germ cell apoptosis in the human testis in vitro Am. J. Physiol. 276 1999 E310 E316
150. M.F. Pera, M.J. Blasco Lafita, and J. Mills Cultured stem-cells from human testicular teratomas: The nature of human embryonal carcinoma, and its comparison with two types of yolk-sac carcinoma Int. J. Cancer 40 1987 334 343
151. M. Perrotti, M. Ankem, A. Bancilla, V. deCarvalho, P. Amenta, and R. Weiss Prospective metastatic risk assignment in clinical stage I nonseminomatous germ cell testis cancer: A single institution pilot study Urol. Oncol. 22 2004 174 177
152. I. Petak, and J.A. Houghton Shared pathways: Death receptors and cytotoxic drugs in cancer therapy Pathol. Oncol. Res. 7 2001 95 106
153. O. Petrenko, A. Zaika, and U.M. Moll deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo Mol. Cell Biol. 23 2003 5540 5555
154. M. Piepkorn Melanoma genetics: An update with focus on the CDKN2A(p16)/ARF tumor suppressors J. Am. Acad. Dermatol. 42 2000 705 722
155. J. Pomerantz, N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, and L. Chin The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713 723
156. A.B. Porcaro, S.Z. Antoniolli, N. Maffei, P. Beltrami, M.A. Bassetto, and P. Curti Management of testicular seminoma advanced disease. Report on 14 cases and review of the literature Arch. Ital. Urol. Androl. 74 2002 81 85
157. Pottern (1998). Testicular and penile cancer. In: Ernstoff Heaney Peschel. Oxford, UK: Blackwell Science. Ref Type: Serial (Book, Monograph).
158. C.D. Pozniak, S. Radinovic, A. Yang, F. McKeon, D.R. Kaplan, and F.D. Miller An anti-apoptotic role for the p53 family member, p73, during developmental neuron death Science 289 2000 304 306
159. C.G. Print, and K.L. Loveland Germ cell suicide: New insights into apoptosis during spermatogenesis Bioessays 22 2000 423 430
160. D.E. Quelle, F. Zindy, R.A. Ashmun, and C.J. Sherr Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest Cell 83 1995 993 1000
161. E. Rajpert-De Meyts, J. Bartkova, M. Samson, C.E. Hoei-Hansen, L. Frydelund-Larsen, and J. Bartek The emerging phenotype of the testicular carcinoma in situ germ cell APMIS 111 2003 267 278
162. E.A. Rapley, S. Hockley, W. Warren, L. Johnson, R. Huddart, and G. Crockford Somatic mutations of KIT in familial testicular germ cell tumours Br. J. Cancer 90 2004 2397 2401
163. E.A. Ratovitski, M. Patturajan, K. Hibi, B. Trink, K. Yamaguchi, and D. Sidransky p53 associates with and targets Delta Np63 into a protein degradation pathway Proc. Natl. Acad. Sci. U.S.A. 98 2001 1817 1822
164. J.H. Richburg The relevance of spontan Toxicol. Lett. 112-113 2000 79 86
165. J.H. Richburg, A. Nanez, L.R. Williams, M.E. Embree, and K. Boekelheide Sensitivity of testicular germ cells to toxicant-induced apoptosis in gld mice that express a nonfunctional form of Fas ligand Endocrinology 141 2000 787 793
166. J.P. Richie Role of P53 and MDM2 in treatment response of human germ cell tumors J. Urol. 169 2003 2420 2421
167. G. Riou, M. Barrois, S. Prost, M.J. Terrier, C. Theodore, and A.J. Levine The p53 and mdm-2 genes in human testicular germ-cell tumors Mol. Carcinog. 12 1995 124 131
168. G. Riou, M.G. Le, J.P. Travagli, A.J. Levine, and U.M. Moll Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma J. Natl. Cancer Inst. 85 1993 1765 1767
169. K.A. Robertson, H.A. Bullock, Y. Xu, R. Tritt, E. Zimmerman, and T.M. Ulbright Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation Cancer Res. 61 2001 2220 2225
170. E. Rodriguez, S. Mathew, V. Reuter, D.H. Ilson, G.J. Bosl, and R.S. Chaganti Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors Cancer Res. 52 1992 2285 2291
171. I. Rodriguez, C. Ody, K. Araki, I. Garcia, and P. Vassalli An early and massive wave of germinal cell apoptosis is required for the development of functional spermatogenesis EMBO J. 16 1997 2262 2270
172. H. Roelofs, M.C. Mostert, K. Pompe, G. Zafarana, M. van Oorschot, and R.J. van Gurp Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis Am. J. Pathol. 157 2000 1155 1166
173. R. Rosell, M. Taron, A. Barnadas, G. Scagliotti, C. Sarries, and B. Roig Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer Cancer Control 10 2003 297 305
174. M.F. Roussel The INK4 family of cell cycle inhibitors in cancer Oncogene 18 1999 5311 5317
175. M. Ruas, and G. Peters The p16INK4a/CDKN2A tumor suppressor and its relatives Biochim. Biophys. Acta 1378 1998 F115 F177
176. Russel (1990). Hystological and hystopathological evaluation of the testis. Casche River Press. Clearwater. Ref Type: Serial (Book, Monograph).
177. Y. Samuels-Lev, D.J. O'Connor, D. Bergamaschi, G. Trigiante, J.K. Hsieh, and S. Zhong ASPP proteins specifically stimulate the apoptotic function of p53 Mol. Cell 8 2001 781 794
178. H. Schepers, M. Geugien, B.J. Eggen, and E. Vellenga Constitutive cytoplasmic localization of p21(Waf1/Cip1) affects the apoptotic process in monocytic leukaemia Leukemia 17 2003 2113 2121
179. C.L. Schlamp, G.L. Poulsen, T.M. Nork, and R.W. Nickells Nuclear exclusion of wild-type p53 in immortalized human retinoblastoma cells J. Natl. Cancer Inst. 89 1997 1530 1536
180. H.U. Schmelz, M. Abend, K. Kraft, E.W. Hauck, W. Weidner, and D. Van Beuningen Fas/Fas ligand system and apoptosis induction in testicular carcinoma Cancer 95 2002 73 81
181. H.U. Schmelz, J. Meiswinkel, M. Port, E.W. Hauck, M.J. Schwerer, and W. Weidner Apoptosis in non-tumorous adult human testis tissue cmparison of so-called 'normal' testis tissues Urol. Int. 74 2005 349 354
182. H.J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, and C. Kollmannsberger European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Oncol. 15 2004 1377 1399
183. S. Schweyer, A. Soruri, O. Meschter, A. Heintze, F. Zschunke, and N. Miosge Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation Br. J. Cancer 91 2004 589 598
184. M. Selvakumaran, D.A. Pisarcik, R. Bao, A.T. Yeung, and T.C. Hamilton Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines Cancer Res. 63 2003 1311 1316
185. O. Sembritzki, C. Hagel, K. Lamszus, W. Deppert, and W. Bohn Cytoplasmic localization of wild-type p53 in glioblastomas correlates with expression of vimentin and glial fibrillary acidic protein Neurooncol 4 2002 171 178
186. M. Serrano The INK4a/ARF locus in murine tumorigenesis Carcinogenesis 21 2000 865 869
187. M.J. Shamblott, J. Axelman, S. Wang, E.M. Bugg, J.W. Littlefield, and P.J. Donovan Derivation of pluripotent stem cells from cultured human primordial germ cells Proc. Natl. Acad. Sci. U.S.A. 95 1998 13726 13731
188. M.D. Shelley, K. Burgon, and M.D. Mason Treatment of testicular germ-cell cancer: A cochrane evidence-based systematic review Cancer Treat. Rev. 28 2002 237 253
189. C.J. Sherr The INK4a/ARF network in tumour suppression Nat. Rev. Mol. Cell Biol. 2 2001 731 737
190. H. Shimodaira, A. Yoshioka-Yamashita, R.D. Kolodner, and J.Y. Wang Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin Proc. Natl. Acad. Sci. U.S.A. 100 2003 2420 2425
191. A.P. Sinha Hikim, Y. Lue, M. Diaz-Romero, P.H. Yen, C. Wang, and R.S. Swerdloff Deciphering the pathways of germ cell apoptosis in the testis J. Steroid Biochem. Mol Biol. 85 2003 175 182
192. A.P. Sinha Hikim, and R.S. Swerdloff Hormonal and genetic control of germ cell apoptosis in the testis Rev. Reprod. 4 1999 38 47
193. N.E. Skakkebaek, J.G. Berthelsen, A. Giwercman, and J. Muller Carcinoma-in-situ of the testis: Possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma Int. J. Androl. 10 1987 19 28
194. R.I. Skotheim, S.M. Kraggerud, S.D. Fossa, A.E. Stenwig, T. Gedde-Dahl Jr., and H.E. Danielsen Familial/bilateral and sporadic testicular germ cell tumors show frequent genetic changes at loci with suggestive linkage evidence Neoplasia 3 2001 196 203
195. R.I. Skotheim, and R.A. Lothe The testicular germ cell tumour genome APMIS 111 2003 136 150
196. D.C. Spierings, E.G. de Vries, A.J. Stel, R.N. te, E. Vellenga, and S. de Jong Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis Oncogene 23 2004 4862 4872
197. D.C. Spierings, E.G. de Vries, E. Vellenga, and S. de Jong Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line Cell Death Differ 10 2003 808 822
198. D.C. Spierings, E.G. de Vries, E. Vellenga, and S. de Jong The attractive Achilles heel of germ cell tumours: An inherent sensitivity to apoptosis-inducing stimuli J. Pathol. 200 2003 137 148
199. R. Stad, N.A. Little, D.P. Xirodimas, R. Frenk, A.J. van der Eb, and D.P. Lane Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms EMBO Rep. 2 2001 1029 1034
200. R.A. Steinman, and D.E. Johnson p21WAF1 prevents down-modulation of the apoptotic inhibitor protein c-IAP1 and inhibits leukemic apoptosis Mol. Med. 6 2000 736 749
201. T. Strohmeyer, P. Reissmann, C. Cordon-Cardo, M. Hartmann, R. Ackermann, and D. Slamon Correlation between retinoblastoma gene expression and differentiation in human testicular tumors Proc. Natl. Acad. Sci. U.S.A 88 1991 6662 6666
202. S. Stumm, A. Meyer, M. Lindner, G. Bastert, D. Wallwiener, and B. Guckel Paclitaxel treatment of breast cancer cell lines modulates Fas/Fas ligand expression and induces apoptosis which can be inhibited through the CD40 receptor Oncology 66 2004 101 111
203. A. Sugihara, S. Saiki, M. Tsuji, T. Tsujimura, Y. Nakata, and A. Kubota Expression of Fas and Fas ligand in the testes and testicular germ cell tumors: An immunohistochemical study Anticancer Res. 17 1997 3861 3865
204. R.F. Suijkerbuijk, R.J. Sinke, A.M. Meloni, J.M. Parrington, J. van Echten, and B. de Jong Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ-cell tumors revealed by fluorescence in situ hybridisation Cancer Genet. Cytogenet. 70 1993 85 93
205. A. Suzuki, Y. Tsutomi, K. Akahane, T. Araki, and M. Miura Resistance to Fas-mediated apoptosis: Activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP Oncogene 17 1998 931 939
206. M.V. Swamy, C.R. Herzog, and C.V. Rao Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53 Cancer Res. 63 2003 5239 5242
207. K. Takeda, A. Matsuzawa, H. Nishitoh, and H. Ichijo Roles of MAPKKK ASK1 in stress-induced cell death Cell Struct. Funct. 28 2003 23 29
208. T. Taniguchi, M. Tischkowitz, N. Ameziane, S.V. Hodgson, C.G. Mathew, and H. Joenje Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat. Med. 9 2003 568 574
209. The International Testicular Cancer Linkage Consortium, 1998. Candidate regions for testicular cancer susceptibility genes. APMIS 106: 64-70.
210. Q. Tian, H.F. Frierson Jr., G.W. Krystal, and C.A. Moskaluk Activating c-kit gene mutations in human germ cell tumors Am. J. Pathol. 154 1999 1643 1647
211. K.K. Tsai, and Z.M. Yuan c-Abl stabilizes p73 by a phosphorylation- augmented interaction Cancer Res. 63 2003 3418 3424
212. T.M. Ulbright Germ cell tumors of the gonads: A selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues Mod. Pathol. 18 Suppl. 2 2005 S61 S79
213. United Kingdom Testicular Cancer Study Group, 1994. Aetiology of testicular cancer: Association with congenital abnormalities, age at puberty, infertility, and exercise. BMJ 308: 1393-1399.
214. N.J. Vogelzang, D. Bronson, D. Savino, R.L. Vessella, and E.F. Fraley A human embryonal-yolk sac carcinoma model system in athymic mice Cancer 55 1985 2584 2593
215. N.J. Vogelzang, E.E. Fraley, P.H. Lange, J. Torkelson, S. Levitt, and B.J. Kennedy Stage II nonseminomatous testicular cancer: A 10-year experience J. Clin. Oncol. 1 1983 171 178
216. F.E. von Eyben Chromosomes, genes, and development of testicular germ cell tumors Cancer Genet. Cytogenet. 151 2004 93 138
217. A.T. von Keitz, H. Riedmiller, K. Neumann, W. Gutschank, and C. Fonatsch Establishment and characterization of a seminoma cell-line (S2) Investig. Urol. (Berl.) 5 1994 28 31
218. Q. Waisfisz, A. Miyazato, J.P. De Winter, J.M. Liu, and H. Joenje Analysis of baseline and cisplatin-inducible gene expression in Fanconi anemia cells using oligonucleotide-based microarrays BMC Blood Disord. 2 2002 5
219. H. Wang, H. Wang, S.N. Powell, G. Iliakis, and Y. Wang ATR affecting cell radiosensitivity is dependent on homologous recombination repair but independent of nonhomologous end joining Cancer Res. 64 2004 7139 7143
220. N. Wang, B. Trend, D.L. Bronson, and E.E. Fraley Nonrandom abnormalities in chromosome 1 in human testicular cancers Cancer Res. 40 1980 796 802
221. X. Wang, M. Hafezparast, and J.R. Masters Complementation analysis of testis tumor cells Cancer Genet. Cytogenet. 98 1997 56 62
222. J.D. Weber, L.J. Taylor, M.F. Roussel, C.J. Sherr, and D. Bar-Sagi Nucleolar Arf sequesters Mdm2 and activates p53 Nat. Cell. Biol. 1 1999 20 26
223. I. Weissbach, and R. Bussar-Maatz Pathogenesis, diagnosis and therapy of testicular tumors Urologe A. 35 1996 163 172
224. C. Welsh, R. Day, C. McGurk, J.R. Masters, R.D. Wood, and B. Koberle Reduced levels of XPA ERCC1 and XPF DNA repair proteins in testis tumor cell lines Int. J. Cancer 110 2004 352 361
225. J.C. Wong, N. Alon, C. Mckerlie, J.R. Huang, M.S. Meyn, and M. Buchwald Targeted disruption of exons 1-6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia Hum. Mol. Genet. 12 2003 2063 2076
226. D.P. Xirodimas, C.W. Stephen, and D.P. Lane Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53 Exp. Cell Res. 270 2001 66 77
227. A. Yang, M. Kaghad, Y. Wang, E. Gillett, M.D. Fleming, and V. Dotsch p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol. Cell 2 1998 305 316
228. A. Yang, and F. McKeon P63 and P73: P53 mimics, menaces and more Nat. Rev. Mol. Cell Biol. 1 2000 199 207
229. X.M. Yin, K. Wang, A. Gross, Y. Zhao, S. Zinkel, and B. Klocke Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis Nature 400 1999 886 891
230. Y. Yin, B.C. Stahl, W.C. DeWolf, and A. Morgentaler P53 and Fas are sequential mechanisms of testicular germ cell apoptosis J. Androl. 23 2002 64 70
231. A.I. Zaika, N. Slade, S.H. Erster, C. Sansome, T.W. Joseph, and M. Pearl DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors J. Exp. Med. 196 2002 765 780
232. D.B. Zamble, Y. Mikata, C.H. Eng, K.E. Sandman, and S.J. Lippard Testis-specific HMG-domain protein alters the responses of cells to cisplatin J. Inorg. Biochem. 91 2002 451 462
233. X. Zhang, N. Yamamoto, S. Soramoto, and I. Takenaka Cisplatin-induced germ cell apoptosis in mouse testes Arch. Androl. 46 2001 43 49
234. Y. Zhang, N. Fujita, and T. Tsuruo Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis Oncogene 18 1999 1131 1138
235. Y. Zhang, and Y. Xiong Control of p53 ubiquitination and nuclear export by MDM2 and ARF Cell Growth Differ. 12 2001 175 186
236. K.C. Zimmermann, C. Bonzon, and D.R. Green The machinery of programmed cell death Pharmacol. Ther. 92 2001 57 70